MedTrace Logo

Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin

NCT00022178 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-09-20

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for metastatic cancer of an unknown site of origin.

PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have metastatic cancer of an unknown site of origin.

Conditions

  • Carcinoma of Unknown Primary

Interventions

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

epirubicin hydrochloride

DRUG

fluorouracil

DRUG

vincristine sulfate

Sponsors & Collaborators

  • The Christie NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Juan W. Valle, MD · The Christie NHS Foundation Trust

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00022178 on ClinicalTrials.gov